Survival of transplant recipients after lymphoma diagnosis is influenced by FCGR3A genotype. Homozygous carriers of the high-affinity V allele show improved survival in discovery (VV 69% ± 11%; VF 36% ± 8%; FF 42% ± 8%; A) and validation (VV 64% ± 10%; VF 33% ± 7%; FF 46% ± 7%; B) cohort. Improved survival of VV carrying patients is not exclusively related to increased efficacy of rituximab, as a similar effect on survival is evident before (VV 58% ± 13%; VF/FF 35% ± 6%; C) and after (VV 70% ± 9%; VF/FF 42% ± 5%; D) the introduction of rituximab in 1997.